Advertisement


Jonathan E. Rosenberg, MD, on Urothelial Cancer: Results From EV-103, Cohort K on Enfortumab Vedotin and Pembrolizumab

ESMO Congress 2022

Advertisement

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses recent findings on the safety and antitumor activity of enfortumab vedotin-ejfv given intravenously as monotherapy or in combination with pembrolizumab to previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (Abstract LBA73).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
EV-103 Cohort K, was a randomized Phase 2 study to determine the anti-tumor activity of enfortumab monotherapy or enfortumab and pembrolizumab as combination therapy in cisplatin-ineligible metastatic urothelial cancer patients who had not received treatment for metastatic disease. The first-line therapeutic options for patients who are cisplatin-ineligible, unfortunately, remain somewhat limited. Gemcitabine and carboplatin has modest activity and nivolumab maintenance is only available to patients who respond or have stable disease. Checkpoint inhibitor therapy as monotherapy is restricted to patients who are PD-L1-positive with atezolizumab or who are ineligible for platinum. EV and pembro, had previously been shown to have monotherapy activity in the second and third line setting leading to clinical benefit and improved survival in that setting. And this provided the rationale for testing the combination in EV-103. The first report of this combination was cohort A, which was recently published in JCO, which showed a 73% response rate and an encouraging safety profile. And as a result, received FDA breakthrough therapy designation. EV-103 is a multi cohort study, and Cohort K is a randomized cohort to try to demonstrate the contribution of components of pembrolizumab and enfortumab to the activity in the first line setting that we observed. The sample size was based on trying to refine the estimate of the response rate, and it's important to note that this is a non-comparative Phase 2 study versus platinum-eligible metastatic urothelial cancer patients. The primary endpoint was response rate, and the response rate in this trial was 64.5% among patients receiving enfortumab vedotin, and pembrolizumab. The response rate for enfortumab monotherapy was 45%, which was certainly consistent with what we've seen in previous results of single agent therapy. Enfortumab and pembro led to 10.5% of patients having complete responses. And the median time to response for both arms, was about two months, and the median number of cycles received for EV-pembro was 11 and eight for EV monotherapy. When looking at the responses, 97% of patients experience tumor regression and activity was seen regardless of PD-L1 status. The median progression free survival has not yet been reached with EV and pembro and the median overall survival is expected to change as time goes on, but was 22 months. The duration of response for EV-pembro was not reached, and about almost two thirds of patients were still responding at one year. There was not an association with nicotiflorin expression. Toxicity of EV and pembro did not reveal any new and unexpected toxicities. There was more skin toxicity with the combination compared to EV monotherapy, and this is expected because EV and pembro both independently have skin toxicity rashes, in particular as an overlapping side effect. Perhaps there might have been slightly more pneumonitis in the EV and pembro arm, but not dramatically increased compared to what you might expect with pembrolizumab. Peripheral neuropathy was seen in 60% of patients, although it was only grade three in 2.5%. Hyperglycemia was present in 14.5% of patients in grade three and 6.6% of patients, and in fact, similar to EV monotherapy. The pembrolizumab adverse events of special interests seem similar as to what had been previously reported, again, with the exception of severe skin reactions. In summary, EV and pembro showed high anti-tumor activity with a response rate of 64.5% in patients with metastatic urothelial cancer ineligible for cisplatin compared to historical controls of gemcitabine and carboplatin where we expect a response rate 35 to 40%. There's a promising PFS and OS, and we expect those data to evolve. The duration of response has not been reached. The monotherapy EV and pembro-EV results were similar to what we've seen previously in EV monotherapy studies, and the combination is being further investigated in three randomized Phase 3 trials. EV-302, which is the confirmatory study for EV-103 Cohort K, in the first line setting for patients regardless of platinum eligibility, randomized to chemotherapy or EV and pembro. And then two Phase 3 neoadjuvant studies looking at perioperative therapy. Based on the results of this study, it's my opinion that EV and pembro has a high likelihood of becoming a standard option for cisplatin eligible metastatic urothelium cancer patients in the near future.

Related Videos

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer (NSCLC); and the ORIENT-31 trial, which compared sintilimab with or without IBI305 (a bevacizumab biosimilar) plus chemotherapy in patients with EGFR-mutated nonsquamous NSCLC who experienced disease progression on EGFR tyrosine kinase inhibitors.

Breast Cancer
Immunotherapy

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes (Abstract LBA13).

Breast Cancer

Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor

Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well as in the subgroup with visceral disease. However, neither met the threshold for statistical significance, and further analyses are planned when more data can be reported. (Abstract LBA15).

Colorectal Cancer

Myriam Chalabi, MD, PhD, on Colon Cancer: New Findings on Neoadjuvant Immune Checkpoint Inhibition

Myriam Chalabi, MD, PhD, of The Netherlands Cancer Institute, discusses data from the NICHE-2 study, which confirms previously reported pathologic responses to short-term neoadjuvant nivolumab plus ipilimumab in patients with locally advanced mismatch repair–deficient colon cancer. Survival data suggest neoadjuvant immunotherapy may become standard of care and allow further exploration of organ-sparing approaches. (Abstract LBA7).

Kidney Cancer

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Cohort 1 of the LITESPARK-003 study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC), and the KEYNOTE-B61 study of pembrolizumab plus lenvatinib as first-line treatment for non–clear cell RCC (Abstracts 1447O and 1448O).

Advertisement

Advertisement




Advertisement